Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.65 |
| ▸ | MAPT | P10636 | 6/20 | 0.65 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | RAD52 | P43351 | 1/20 | 0.63 |
| ▸ | GFER | P55789 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.61 |
| ▸ | MEN1 | O00255 | 5/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4186740 | 0.85 | RAD52 (0.81) | ALDH1A1MAPTLMNARAD52GFER | |
| SCHEMBL13102353 | 0.84 | LMNA (0.72) | ALDH1A1MAPTLMNARAD52GFER | |
| SCHEMBL4188747 | 0.82 | KMT2A (0.68) | ALDH1A1MAPTLMNARAD52GFER | |
| SCHEMBL7133165 | 0.79 | ALDH1A1 (0.56) | ALDH1A1MAPTKMT2AMEN1L3MBTL1 | |
| SCHEMBL1644836 | 0.79 | ALDH1A1 (0.97) | ALDH1A1MAPTLMNARAD52GFER | |
| SCHEMBL4194331 | 0.79 | ALDH1A1 (1.00) | ALDH1A1MAPTLMNAKMT2AMEN1 | |
| SCHEMBL1646961 | 0.78 | ALDH1A1 (1.00) | ALDH1A1MAPTLMNARAD52GFER | |
| SCHEMBL13803997 | 0.77 | ALDH1A1 (0.61) | ALDH1A1MAPTLMNARAD52GFER | |
| SCHEMBL4820185 | 0.76 | RAD52 (0.67) | ALDH1A1MAPTLMNARAD52GFER | |
| SCHEMBL6947771 | 0.76 | L3MBTL1 (0.59) | ALDH1A1KMT2AMEN1TSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302547-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2012-11-29 | — | — | US | disclosed |
| US-8263772-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| US-20090093456-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302547-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | ALDH1A1 1473/4885MAPT 2293/4885LMNA 4112/4885 |
| US-20090093456-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | ALDH1A1 1267/4885MAPT 2244/4885LMNA 4299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.